RBC Capital Lifts Insulet (PODD) PT to $365 on Strong Momentum, Q3 Guidance Optimism

Core Insights - Insulet Corporation (NASDAQ:PODD) is identified as a top growth stock for the next five years, with RBC Capital raising its price target to $365 from $350, maintaining an Outperform rating due to attractive valuations and opportunities in the Medical Supplies & Devices sector [1][2][3] Company Overview - Insulet Corporation specializes in developing, manufacturing, and selling insulin delivery systems for individuals with insulin-dependent diabetes, both in the US and internationally [4] Market Sentiment - Investor sentiment is positive ahead of Insulet's Q3 earnings report, as management has indicated strong business momentum that is expected to exceed official Q3 guidance, reducing risk for the quarter [2][3] Industry Trends - The MedTech sector is experiencing steady adoption of continuous glucose monitors and insulin pumps, with significant opportunities identified in the Type 2 insulin-intensive market, which enhances Insulet's competitive position [3]